Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Increased physical activity slows down visual field loss in glaucoma patients

15 Nov 2018

Spending more time walking and doing moderate-to-vigorous physical and nonsedentary activities appears to lead to slower rates of visual field (VF) loss in glaucoma patients, according to a study.

The study included 141 older adults (mean age 64.9 years) with suspect or manifest glaucoma. All participants wore accelerometers for 1 week to estimate average steps and minutes of moderate-to-vigorous activity (MVPA) and nonsedentary activity per day.

Pointwise changes in VF sensitivity, the main outcome, was assessed in relation to physical activity measures. Eye mean deviation (MD) at the time of physical activity assessment was –6.6 dB, and average steps per day was 5,613.

Based on pointwise VF sensitivity, the unadjusted average rate of VF loss was 0.36 dB/year (95 percent CI, –0.37 to –0.35). In multivariable models, VF loss was slower in patients with higher number of steps per day (1,000 daily steps: 0.007 dB/year; p<0.001) and increased MVPA (10 more minutes daily: 0.003 dB/year; p<0.001) and nonsedentary activity (30 more minutes per day: 0.007 dB/year; p=0.005).

Risk factors for accelerated VF loss included older age, non-Caucasian race, glaucoma surgery, cataract surgery and moderate baseline VF damage (–6 dB≥ MD >–12 dB). Similar associations between baseline accelerometer-measured physical activity and rates of VF loss were seen over other time periods (eg, within 1, 3 and 5 years of activity assessment).

The present data highlight the potential of physical activity for delaying VF loss in glaucoma, with an additional 5,000 daily steps or 2.6 hours of nonsedentary physical activity decreasing the average rate of VF loss by roughly 10 percent, researchers said.

More prospective studies are warranted to explore whether physical activity can slow VF loss in glaucoma and/or if progressive VF loss results in activity restriction, they added. If positively confirmed, this would mark physical activity as a novel modifiable risk factor for preventing glaucoma damage.

Editor's Recommendations
Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.